Comparative Pharmacology
Head-to-head clinical analysis: CALCIUM CHLORIDE 10 versus SODIUM PHOSPHATES IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIUM CHLORIDE 10 versus SODIUM PHOSPHATES IN PLASTIC CONTAINER.
CALCIUM CHLORIDE 10% vs SODIUM PHOSPHATES IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Sodium phosphates increase serum phosphate concentration, promoting renal excretion of calcium and phosphate, and inducing osmotic diarrhea to cleanse the colon.
IV: 500 mg to 1 g (5-10 mL of 10% solution) administered slowly at a rate not exceeding 0.5-1 mL/min; may be repeated every 1-3 days based on serum calcium levels.
Oral: 30-90 mL (equivalent to 3.75-11.25 g sodium phosphate) once daily, preferably in the morning, with a full glass of water. Dose may be increased up to 240 mL per day in divided doses. Rectal enema: 118 mL (monobasic sodium phosphate 19 g, dibasic sodium phosphate 7 g) as a single dose.
None Documented
None Documented
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Terminal half-life of absorbed phosphate is approximately 0.5–1 hour in patients with normal renal function. Clinically, effects on serum phosphate are transient and depend on renal clearance.
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
Primarily renal (≥90% as inorganic phosphate and sodium). Fecal elimination is minimal (<5%) via unabsorbed phosphate.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement